Patients with resectable pancreatic cancer from the Virginia Mason Pancreaticobiliary Cancer Database were included in an analysis to determine the impact of neoadjuvant chemotherapy alone in this patient population. Data from this analysis were presented at the 2020 Gastrointestinal (GI 2020) Cancers Symposium by lead author, Vincent Picozzi, MD Read more . . .
Patients with pancreatic cancer typically undergo chemotherapy and/or chemoradiation followed by surgery with the intent to cure. However, this treatment landscape lacks data on sequencing chemotherapy in patients to optimize response. Treatment following surgery at this time remains unclear.